JPRN-UMIN000039605招募中未知
intedanib treatment for the patients with systemic scleroderma-associated interstitial lung disease-a prospective observational study - Nintedanib for the patients with SSc-ILD
Department of Respiratory Medicine, Juntendo University Hospital0 个研究点目标入组 100 人开始时间: 2020年2月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Difficulty obtaining patients' consent (2) Severe heart disease (3) AST >=2*ULN, ALT >=2*ULN, or T-bil >=2*ULN (4) Pregnancy (5) Complication with other CTD, RA, SLE,PM/DM, MCTD, SjS, Behcet's disease, and vasculitis (6) Coexistence with pulmonary arterial hypertension, bronchial asthma, Malignant tumor, sarcoidosis, bronchiectasis, respiratory infection (7) A patient who already receive nintedanib or other anti-fibrotic agents (8) A patient with risk of fatal bleeding (9) Past history of thrombosis less than 3 months (10) A patient who started clinical trials less than 3 months (11) A patient improper to this clinical trial according to the decision of a principal investigator
研究者
相似试验
进行中（未招募）
1 期
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)Immune thrombocytopeniaMedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851CTIS2023-505788-35-00Fakultni Nemocnice Hradec Kralove73
招募中
2 期
intedanib for IPF patients with resected NSCLC in JAPAN Phase 2 studyIdiopathic pulmonary fibrosis, Non-Small Cell Lung CancerIPF, Idiopathic pulmonary fibrosis, NSCLC, Non-Small Cell Lung CancerJPRN-jRCT1061220064Okada Morihito30
招募中
不适用
Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)Idiopathic pleuroparenchymal fibroelastosisJPRN-UMIN000042946Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University10
已完成
3 期
Immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - a prospective, double-blind, randomized, placebo-controlled clinical trialviral mediated heartfailure1002859310047438NL-OMON33416Sanquin Plasmaproducten50
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60